Bisphosphonates were linked to lower dementia risk in older adults with osteoporosis
A widely used class of osteoporosis medicines may do more than preserve bone density. In a population-based Hong Kong study of more than 120,000 adults aged 60 and older, nitrogen-containing bisphosphonates were associated with a lower risk of Alzheimer’s disease and related dementias than no osteoporosis treatment at all, and the signal was stronger when those drugs were compared with other osteoporosis therapies.
The finding is striking because these agents are already deeply embedded in routine bone care. Alendronate and zoledronate, two of the best-known bisphosphonates, work by slowing bone resorption and helping maintain skeletal strength. In older patients who already face a high fracture burden, a drug that might also be linked to brain protection would immediately widen the clinical conversation around prevention.
One sentence stands out in the data: the dementia association moved in the same direction across comparisons.
A 24% lower dementia risk emerged in the active-comparator analysis
Investigators at the University of Hong Kong reviewed electronic medical records collected between 2005 and 2020, focusing on patients with osteoporosis or fragility fractures. Fragility fractures occur after relatively minor trauma because bone has already become weakened, and they often mark a frailer older population with overlapping neurological vulnerability. In that cohort, patients receiving NBPs had a 16% lower risk of Alzheimer’s disease and related dementias compared with patients who received no osteoporosis medication.
The separation widened in the comparison against other osteoporosis drugs. In that analysis, NBP use was associated with a 24% lower dementia risk. For a chronic neurodegenerative outcome, the active-comparator design matters because it helps move the question beyond simple treatment-versus-no-treatment contrasts. Patients who receive osteoporosis medication may differ from untreated patients in health behaviors, access to care, or severity of underlying disease, so the comparison against another drug class gives the signal more clinical weight, even if it still cannot prove causation.
Women and patients with hip fractures appeared to show particularly strong associations between NBP treatment and lower dementia risk. The study also estimated that treating 48 patients with NBPs for five years could potentially prevent one case of dementia, if the observed relationship reflects a true protective effect rather than residual confounding.
Why a bone drug might matter in the brain
The biology is plausible enough to deserve attention. Osteoporosis and dementia commonly converge in the same aging patient, and both are tied to advancing age, female sex, and physical inactivity. Prior work from the same Hong Kong group found that osteoporosis and fractures were independent risk factors for dementia, while people already living with dementia had a higher likelihood of falling and breaking bones. In that setting, bone loss may be more than a skeletal problem; it may be part of a broader frailty phenotype that mirrors declining reserve across organ systems.
Bisphosphonates may also influence pathways that reach beyond bone turnover. Research interest has grown around shared inflammatory and metabolic mechanisms that could affect both osteoporosis and Alzheimer’s disease. If these drugs alter systemic processes linked to neurodegeneration, the benefit would not have to arise from direct penetration into the brain to matter clinically. A medication that reduces fractures, preserves mobility, and possibly dampens disease pathways tied to cognitive decline would fit neatly into geriatric care, where a single therapy often needs to address several risks at once.
The existing approval status of NBPs gives the finding immediate practical relevance. New dementia drugs are expensive, not suitable for all patients, and still leave major questions about real-world effectiveness. An established osteoporosis treatment is easier to deploy, easier to study, and already familiar to clinicians who manage older adults.
Observational data point to a hypothesis, not a conclusion
The study design also sets clear limits. This was an observational analysis of medical records, not a randomized trial, so the results cannot establish that bisphosphonates prevent dementia. Treatment choice may reflect baseline differences in frailty, adherence, physician prescribing patterns, or the severity of bone disease itself. Even careful analyses can miss factors that influence both who gets the drug and who later develops cognitive decline.
Still, the pattern is difficult to ignore. Professor Cheung Ching-lung of HKUMed described the findings as evidence that NBPs may offer dual benefit by strengthening bones and potentially reducing ADRD risk, while also providing an empirical basis for future research on cognitive decline. That framing is measured, and it fits the data. The study does not claim the question is settled. It makes the case that the question is now worth testing more rigorously.
The burden of dementia is growing fast. More than 55 million people worldwide are living with dementia, and projections point much higher by mid-century. Against that backdrop, even a modest preventive effect from an already available medication could matter if the association holds up in prospective studies.
Older adults with fractures may be the most relevant group to study next
The subgroup signal in women and in patients with hip fractures deserves particular attention. Hip fracture often signals advanced skeletal fragility, loss of mobility, and a steep rise in dependence after injury. Those patients may stand at the intersection of two spiraling risks: recurrent falls and cognitive decline. If NBPs are truly protective, the patients most likely to benefit may be those already entering that high-risk zone.
For now, the safest reading is straightforward. Bisphosphonates remain osteoporosis drugs first and foremost, but this large Hong Kong study suggests they may be linked to lower dementia risk in older adults with fragile bones or prior fractures. The next step is not to treat the association as proof, but to test whether the signal survives in studies designed to answer the prevention question directly.